Pomerantz Law Firm Investigates Claims on Behalf of PepGen Inc. Investors Following FDA's Clinical Hold Announcement

Pomerantz Law Firm Investigates PepGen Inc. Claims

Pomerantz LLP, a renowned law firm known for its expertise in corporate and securities class litigation, has announced an investigation concerning PepGen Inc. (NASDAQ: PEPG) on behalf of its investors. The firm is delving into claims that suggest PepGen and several of its officers or directors could have engaged in securities fraud or other illegal business practices, raising concerns about their accountability in light of recent developments.

This investigation has garnered attention following a significant announcement from PepGen on March 4, 2026. The company disclosed that the U.S. Food and Drug Administration (FDA) had placed a partial clinical hold on its FREEDOM2-DM1 Phase 2 clinical trial, which is evaluating the drug PGN-EDODM1 for treating patients with myotonic dystrophy type 1 (DM1). The FDA's concerns were reportedly related to the pharmacology and toxicology studies that PepGen had submitted prior to the trial.

As immediate repercussions unfolded, PepGen's stock witnessed a sharp decline. On March 5, 2026, shares dropped by $1.25, reflecting an 18.57% decrease, and closed at $5.50 per share. This dramatic fall highlighted the immediate financial impact that regulatory setbacks can have on investor trust and stock market performance.

Pomerantz LLP advises all investors impacted by this news to reach out for further information. They have emphasized the importance of holding corporations accountable for transparency and integrity in their business operations. The firm has a storied history of advocating for victims of corporate misconduct, having recovered substantial damages for class action members over its 85-year history.

As the investigation unfolds, affected investors are encouraged to consider joining a class action to strengthen their claims. Legal expert Danielle Peyton of Pomerantz LLP is available for communication regarding this investigation, enabling investors to understand their options moving forward.

The firm operates globally, with offices located in major cities such as New York, Chicago, and London, emphasizing their capacity to handle complex legal matters involving corporate misconduct. Their legacy, attributed to founder Abraham L. Pomerantz, underscores their ongoing commitment to fighting for justice on behalf of investors.

Commercial entities that experience sudden regulatory challenges often face difficulties that can ripple through the market, impacting not only investors but also stakeholders who rely on the company's success for their livelihoods. The investigation into PepGen encapsulates the increasing scrutiny that companies face regarding their operations and compliance with federal regulations.

In conclusion, the situation surrounding PepGen serves as a crucial reminder of the volatility that can accompany pharmaceutical trials and the implications such regulatory actions can have on stock performance. Investors and analysts will be closely monitoring the situation as it develops, and Pomerantz LLP's involvement signifies that legal recourse is being explored on behalf of those affected. Stay tuned as more updates emerge regarding this investigation and its potential outcomes for PepGen and its investors.